Additional study centre for the Magnetic Resonance Outcome (MRO) study in Europe
06/12/2024
Since 27 May 2024, the Helios University Hospital Wuppertal, Witten/Herdecke University, has joined the MRO study to evaluate the ClearCoast™ MRI system. The team around Prof. Dr Vesna Bjelic-Radisic, Chief Physician of the Breast Centre and the Department of Senology, who is leading the study, is pleased to be participating in the MRO study as a study centre. The aim of the study is to reduce the number of re-operations.
The ClearCoast™ MRI system enables precise intraoperative assessment of the surgical margins in breast-conserving cancer surgery. Positive margins can be identified by the system even without radiological expertise during the initial operation. This means that any necessary resection can be carried out immediately and a second operation can often be avoided. The surrounding healthy tissue can be preserved as far as possible.
With the methods currently used, it is not possible to prevent the need for a follow-up resection or even a mastectomy in 15-30 per cent of cases.1
The MRO study was launched in June 2021 at Agaplesion Markus Hospital in Frankfurt am Main under the direction of Professor Dr Marc Thill. Since June 2023, the Western General Hospital in Edinburgh has also been participating under the leadership of Professor Dixon and Dr Kulkarni.
The manufacturer of the ClearCoast™ system and sponsor of the study is ClearCut Medical Ltd. from Israel. pfm medical gmbh is the exclusive distribution partner in Europe.
Further information on the ClearCoast™ MRI system can be found here.
Sources:
[1] Benjamin W. Maloney, David M. McClatchy, Brian W. Pogue, Keith D. Paulsen, Wendy A. Wells, Richard, J. Barth, Jr. "Review of methods for intraoperative margin detection for breast conserving surgery," J. Biomed. Opt. 23(10), 100901 (2018), doi: 10.1117/1.JBO.23.10.100901
